Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Alan Williams, Rina Mbofung, Daniel Morales-Mantilla, Brian Groff, Alison O'Connor, Binzhong Li, Ramesh Janani, Betsy Rezner, Mark Jelcic, Yijia Pan, Tom Lee, Karl-Johan Malmberg, Maksim Mamonkin, John Goulding, Jode Goodridge, Bahram Valamehr

Blood (2024) 144 (Supplement 1): 503.

https://doi.org/10.1182/blood-2024-210846

Published: 2024

Journal Articles

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

Quirin Hammer, Karlo Perica, Rina M Mbofung, Hanna van Ooijen, Erika Varady, Mark Jelcic, Yijia Pan, Pouria Momayyezi, Brian Groff, Ramzey Abujarour, Silje Zandstra Krokeide, Tom Lee, Alan M Williams, Jode P Goodridge, Bahram Valamehr, Bjorn Onfelt, Michel Sadelain, Karl-Johan Malmberg

Blood (2022) 140 (Supplement 1): 1165–1166.

https://doi.org/10.1182/blood-2022-163086

Published: 2022

Journal Articles

Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma

Kim Anh Giang, Mizuha Kanaya, Thorstein Boxaspen, Minoru Kanaya, Silje Zandstra Krokeide, Yumei Diao, Fredrik Schjesvold, Fredrik Lehmann, Johan Nilvebrant, Stefan Svensson Gelius, Karl-Johan Malmberg, Per-Åke Nygren

Blood (2022) 140 (Supplement 1): 10699–10700.

https://doi.org/10.1182/blood-2022-164753

Published: 2022

Journal Articles

Perturbed NK-cell homeostasis associated with disease severity in chronic neutropenia

Ebba Sohlberg, Aline Pfefferle, Eivind Heggernes Ask, Astrid Tschan-Plessl, Benedikt Jacobs, Herman Netskar, Susanne Lorenz, Minoru Kanaya, Mizuha Kosugi-Kanaya, Stephan Meinke, Anette Mörtberg, Petter Höglund, Mikael Sundin, Göran Carlsson, Jan Palmblad, Karl-Johan Malmberg

Blood (2022) 139 (5): 704–716.

https://doi.org/10.1182/blood.2021013233

Published: 2022

Includes: Supplemental data

Journal Articles

KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries

Joshua A Fein, Roni Shouval, Elizabeth Krieger, Henning Baldauf, Katharina Fleischhauer, Nicolaus Kroeger, Mary M. Horowitz, Martin Maiers, Karl-Johan Malmberg, Jeffrey S. Miller, Mohamad Mohty, Arnon Nagler, Rizwan Romee, Johannes Schetelig, Stephen R. Spellman, Amir Ahmed Toor, Tao Wang, Daniel J. Weisdorf, John Koreth

Blood (2021) 138 (Supplement 1): 419.

https://doi.org/10.1182/blood-2021-149935

Published: 2021

Journal Articles

Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection

Rina M Mbofung, Alan M Williams, Ken Hayama, Yijia Pan, Brian Groff, Thomas Dailey, Sonia Reyes, Sajid Mahmood, Ketan Mathavan, Greg Bonello, Quirin Hammer, Karl-Johan Malmberg, Tom Lee, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2021) 138 (Supplement 1): 2795.

https://doi.org/10.1182/blood-2021-153484

Published: 2021

Journal Articles

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy

Alan M Williams, Ken Hayama, Yijia Pan, Brian Groff, Rina M Mbofung, Lauren Fong, Nicholas Brookhouser, Berhan Mandefro, Ramzey Abujarour, Tom Lee, Quirin Hammer, Karl-Johan Malmberg, Maksim Mamonkin, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2021) 138 (Supplement 1): 4800.

https://doi.org/10.1182/blood-2021-153614

Published: 2021

Journal Articles

Systems-Level Analysis of the Immune Repertoire in Neutropenia Reveal Arrested NK Cell Differentiation and Exhaustion

Ebba Sohlberg, Aline Pfefferle, PhD, Eivind Heggernes Ask, MD, Astrid Tschan-Plessl, MD, Benedikt Jacobs, MD, Suzanne Lorenz, PhD, Stephan Meinke, Petter Hoglund, MD PhD, Mikael Sundin, MDPhD, Goran Karlsson, MDPhD, Jan Palmblad, MD PhD, Karl-Johan Malmberg, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141981

Published: 2020

Journal Articles

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138527

Published: 2020

Journal Articles

Innate-like Chemokine Receptor Profile and Migratory Behaviour By Terminally Differentiated and Educated NK Cells

Mieszko Lachota, Daniel Alfredo Palacios, MSc, Dennis Clement, MSc, Eivind Heggernes Ask, MD, Hanna Julie Hoel, MSc, Merete Thune Wiiger, PhD, Marianna Vincenti, MD, Magdalena Winiarska, Radoslaw Zagozdzon, MD PhD, Karl-Johan Malmberg, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-140944

Published: 2020

Journal Articles

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

Jode P Goodridge, PhD, Ryan Bjordahl, PhD, Sajid Mahmood, PhD, John Reiser, PhD, Svetlana Gaidarova, MS, Robert Blum, MS, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Yu-Waye Chu, MD, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Armin Rehm, Uta Hopken, Bahram Valamehr, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142750

Published: 2020

Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 133.

https://doi.org/10.1182/blood-2019-131138

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

https://doi.org/10.1182/blood-2019-129319

Published: 2019

Journal Articles

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival

Astrid Tschan-Plessl, MD, Eivind Heggernes Ask, Thea Johanne Gjerdingen, Michelle Saetersmoen, Hanna Julie Hoel, Merete Thune Wiiger, Msc, Johanna Olweus, Björn E Wahlin, MD PhD, Amir Horowitz, PhD, Todd A Fehniger, MD PhD, Harald Holte, MD PhD, Arne Kolstad, MD PhD, Karl-Johan Malmberg, MD PhD

Blood (2019) 134 (Supplement_1): 2897.

https://doi.org/10.1182/blood-2019-131359

Published: 2019

Journal Articles

KIR Expression on in Vitro -Derived Natural Killer Cells Does Not Regulate Killing of Allogeneic Targets

Yunzu Michele Wang, MD, Huang Zhu, PhD, Alessa Ruiz-Cisneros, Naveen Heragu, BS, Eivind Heggernes Ask, Hanna Julie Hoel, Karl-Johan Malmberg, MD PhD, Dan S Kaufman, MD PhD

Blood (2018) 132 (Supplement 1): 3705.

https://doi.org/10.1182/blood-2018-99-117151

Published: 2018

Journal Articles

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Emily Chiu, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Sarah Cooley, MD, Helen Chu, PhD, Moyar Q. Ge, PhD, Ryan Bjordahl, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 729.

https://doi.org/10.1182/blood-2018-99-112202

Published: 2018

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

Notch Activation Rescues Exhaustion in CISH -Deleted Human iPSC-Derived Natural Killer Cells to Promote In Vivo Persistence and Enhance Anti-Tumor Activity

Huang Zhu, PhD, Robert Blum, Zhengming Wu, Andres Bahena, Hanna Julie Hoel, Eivind Heggernes Ask, Kun-Liang Guan, PhD, Karl-Johan Malmberg, MD PhD, Dan S Kaufman, MDPhD

Blood (2018) 132 (Supplement 1): 1279.

https://doi.org/10.1182/blood-2018-99-112791

Published: 2018

Journal Articles

Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS

Blood (2018) 132 (Supplement 1): 195.

https://doi.org/10.1182/blood-2018-195

Published: 2018

Journal Articles

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Andreas T Björklund, MD PhD MSc, Mattias Carlsten, MD PhD, Ebba Sohlberg, PhD, Trevor Clancy, Lisa Liu, Mohsen Karimi, PhD, Sarah Cooley, MD, Jeffrey S. Miller, MD, Emma Watz, Björn Engelbrekt Wahlin, Marzia Palma, MD PhD, Lotta Hansson, Per Ljungman, Eva Hellstrom-Lindberg, MD PhD, Hans-Gustaf Ljunggren, Karl-Johan Malmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4458.

https://doi.org/10.1182/blood.V130.Suppl_1.4458.4458

Published: 2017

NARROW

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma

Perturbed NK-cell homeostasis associated with disease severity in chronic neutropenia

KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries

Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection

A Novel Stealth Strategy That Activates Adoptively Transferred Allogeneic Immune Cells and Avoids Rejection for Off-the-Shelf Cell-Based Cancer Therapy

Systems-Level Analysis of the Immune Repertoire in Neutropenia Reveal Arrested NK Cell Differentiation and Exhaustion

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Innate-like Chemokine Receptor Profile and Migratory Behaviour By Terminally Differentiated and Educated NK Cells

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival

KIR Expression on in Vitro -Derived Natural Killer Cells Does Not Regulate Killing of Allogeneic Targets

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Notch Activation Rescues Exhaustion in CISH -Deleted Human iPSC-Derived Natural Killer Cells to Promote In Vivo Persistence and Enhance Anti-Tumor Activity

Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only